



Coordinated Press Release

ENABLE selects new antibiotic candidate

Following the integration of Mutabilis' second programme in ENABLE in April 2018, the ENABLE Portfolio Management Committee has selected a candidate from this programme. The ENABLE project is supported by the Innovative Medicines Initiative (IMI), a Public-Private Partnership jointly funded by the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Romainville, France, 6. November 2019 – Mutabilis, a biopharmaceutical company specialised in research and development of anti-infectious treatments, today announced that their oral combination has been selected as a development candidate for the treatment of complicated urinary tract infections and acute pyelonephritis caused by *E. coli*, *Klebsiella spp.* and *P. mirabilis*. These infections are increasingly caused by bacteria resistant to antibiotics such as fluoroquinolones and cephalosporins.

The Mutabilis candidate combines an oral prodrug of a known beta-lactam of the cephalosporin class with MUT485, an oral prodrug of a novel highly potent beta-lactamase inhibitor that restores the activity of the cephalosporin partner against resistant bacteria and reduces the risk of resistance development. This combination has the potential to become the first novel oral beta-lactam/beta-lactamase inhibitor combination since the introduction of Augmentin in 1981. Use of the oral combination is expected to reduce the use of last-line agents, such as carbapenems, and result in fewer hospital admissions or reduce the length of stay in the hospital.

With this candidate selection, ENABLE has achieved its objective to select two development candidates for the treatment of systemic Gram-negative infections by 2020. This comes at a time when new approaches and molecules to combat drug-resistant bacteria are urgently needed. Pierre Meulien, Executive Director of the Innovative Medicines Initiative, said: "Identifying another promising potential candidate is a massive achievement and a tribute to the ENABLE team, who has combined their expertise to create an excellent platform for early stage antibiotic development. This also demonstrates the added value of the public-private partnership approach in tackling antimicrobial resistance."

In this battle against antimicrobial resistance, small and medium-sized enterprises (SMEs) such as Mutabilis are playing an increasing role. As highlighted by the [Pew Charitable Trusts](#), over 90 percent of the antibiotics in development are pushed forward by small companies rather than large pharmaceutical companies. "SME efforts are the backbone of AMR research, and with valuable EFPIA guidance we want to support their initiatives as best as we can", said Anders Karlén, Leader of the managing entity of ENABLE and Professor at Uppsala University.



About ENABLE

In ENABLE, over 40 European partners from academia and industry, co-led by GlaxoSmithKline and Uppsala University, joined forces in a 6-year project funded by the Innovative Medicines Initiative (IMI) to develop novel antibiotics against key Gram-negative bacteria such as *E. coli*, *K. pneumoniae*, *P. aeruginosa* and *A. baumannii*. ENABLE has rapidly succeeded in building a bottom-up drug development engine with an engaged group of highly competent scientists all working towards the development of new drugs. The first clinical candidate selected by the ENABLE consortium was Apramycin – the press release can be downloaded here. Contact Laura Griestop for any communication related question (info@nd4bb-enable.eu). If you want to stay updated on our progress – register for our newsletter by sending an e-mail to info@nd4bb-enable.eu. ENABLE is part of the ND4BB programme.

The research leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115583, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. The ENABLE project is also financially supported by contributions from Academic and SME partners. www.imi.europa.eu.

About Mutabilis

Mutabilis is a French biopharmaceutical company developing novel antibacterials against Gram-negative infections. Mutabilis has a unique expertise in diazabicyclooctane chemistry and its applications in the discovery of novel antibacterials and beta-lactamase inhibitors. With outstanding stability to hydrolysis by serine- and metallo-beta-lactamases, diazabicyclooctane derivatives are particularly promising to address the most difficult infections, namely those that are resistant to carbapenems. Mutabilis is based in Romainville, near Paris, France and has 27 employees, most of whom are dedicated to research and development.

<http://www.mutabilis.fr>

About IMI

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations and medicines regulators. IMI is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).

<http://www.imi.europa.eu/>